Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CLIFE1 (also known as APC201) is an investigational topical gel formulation combining the local anesthetic lidocaine (2%) and the non-steroidal anti-inflammatory drug (NSAID) diclofenac (0.5%). Developed by the Hospital de Viladecans, it is specifically designed for the management of postoperative pain following benign anorectal surgery (BARS), including procedures such as hemorrhoidectomy, fistulectomy, and fissurectomy. The mechanism of action involves lidocaine's blockade of voltage-gated sodium channels to inhibit nerve conduction and provide rapid analgesia, complemented by diclofenac's inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes to reduce inflammation and provide prolonged pain relief. In the multicenter CLIFE-2010FV clinical trial, CLIFE1 demonstrated superior analgesic efficacy compared to lidocaine-only gel (CLIFE2).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lidocaine + diclofenac (Hospital de Viladecans).